pie chart of 340B covered entity purchases in 2021
The Commonwealth Fund has issued a primer that explores how 340B program growth has spawned controversy over the drug discount program.

Health Policy Think Tank Commonwealth Fund Issues 340B Primer

The Commonwealth Fund, a well-respected think tank focused on promoting a high-performance and equitable healthcare system, published a primer on the 340B program last week, highlighting the program’s growth and the controversy its growth has sparked.    

“We did the report because 340B is often in the news and there are many developments with it, so we wanted to provide some context and information on it for our audience,” Lovisa Gustafsson, the group’s vice president, controlling healthcare costs, told 340B Report. “We do realize it is a very complex topic and not all aspects of the program were addressed in the piece we put out.” She said the Commonwealth Fund may follow up with additional pieces on the 340B program “if this continues to be an area of interest.”   

The Commonwealth Fund published a primer on the 340B program last week highlighting the program’s growth and the controversy its growth has sparked.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

×

*Sign up for news summaries and alerts from 340B Report

Site Footer